Crossbow Therapeutics raised $77 million in a Series B financing round announced on March 13, 2026, co-led by Taiho Ventures and Arkin Bio Capital.12
Funds will support the Phase 1 CROSSCHECK-001 trial of lead candidate CBX-250, targeting pHLA on myeloid cancer cells in AML, CML, MDS, and CMML patients, with data expected end of 2026.12
Financing enables IND submission and Q3 2026 Phase 1 start for CBX-663, targeting TERT-derived pHLA in hematologic and solid tumors.12
CEO Briggs Morrison highlighted the round's role in advancing TCR-mimetic immunotherapies for hard-to-treat cancers.12
New investors include Sixty Degree Capital, Hamilton Square Partners, LifeLink Ventures, Libbs Ventures, and Blood Cancer United’s TAP; existing include Eli Lilly, Pfizer Ventures, MPM BioImpact.12
Preclinical data on CBX-250 and CBX-663 to be presented at AACR 2026 Annual Meeting, April 17-22.2
Sources:
1. https://www.fiercebiotech.com/biotech/crossbow-hits-77m-series-b-round-bankroll-quiver-t-bolts
2. https://www.businesswire.com/news/home/20260313133638/en/Crossbow-Therapeutics-Raises-$77-Million-in-Series-B-Financing-to-Advance-Development-of-TCR-mimetic-Antibody-Therapies-to-Treat-Cancer